Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Open access
Martins, Filipe, Sykiotis, Gerasimos P, Maillard, Michel, Fraga, Montserrat, Ribi, Camillo, Kuntzer, Thierry, Michielin, Olivier, Peters, Solange, Coukos, Georges, Spertini, Francois, Thompson, John A, Obeid, Michel · 2019 · The Lancet Oncology

Abstract

Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxicities for healthcare practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of patients with cancer are increasingly confronted with the therapeutic challenge of treating patients with severe and refractory immune-related adverse events. In this Personal View, we summarise the therapeutic strategies that have been used to manage such toxicities resulting from immune checkpoint inhibitor treatment. On the basis of current knowledge about their pathogenesis, we discuss the use of new biological and non-biological immunosuppressive drugs to treat severe and steroid refractory immune-related adverse events. Depending on the immune infiltrate type that is predominant, we propose a treatment algorithm for personalised management that goes beyond typical corticosteroid use. We propose a so-called shut-off strategy that aims at inhibiting key inflammatory components involved in the pathophysiological processes of immune-related adverse events, and limits potential adverse effects of drug immunosuppression on tumour response. This approach develops on current guidelines and challenges the step-by-step increase approach to drug immunosuppression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30828-3

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 191

Metadata

Authors
Martins, F., Sykiotis, G. P., Maillard, M., Fraga, M., Ribi, C., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., Thompson, J. A., & Obeid, M.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-01
Volume
20
Issue
1
Pages
e54-e64
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2907056240
Cited by
191
References
15
FWCI
10.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30828-3
The paper
Martins, F., Sykiotis, G. P., Maillard, M., Fraga, M., Ribi, C., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., Thompson, J. A., & Obeid, M. (2019). New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30828-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.